

#7

			Silect 1 Of 1			
B/O Form PTO-1449	Atty. Docket Number REF/TONER/289	Serial Number 09/425,289				
U.S. Department of Commerce Patent and Trademark Office	Applicant TONER et al.					
Information Disclosure Statement by Applicant	Filing Date October 22, 1999	Group	1616- 1619			

## U.S. Patent D cuments

Examiner Initial	Document Nu	mber Date	Patentee/Applicant	Class	Subclass	Filing Date if Appropriate
in	5,411,730	5/2/95	Kirpotin et al.	424	322	
				,		

Foreign Patent Documents

Examiner					1	Tran	slation
Initial	Document Number	Publication Date	Country/Agency	Class	Subclass	Yes	No
W	WO 96 18421 A	6/20/96	Lippmann Matthias				
#	EP 0 470 569 A	2/12/92	Takeda Chemical Indust. Ltd.				
à A	WO 94 02106 A	2/3/94	Univ. Texas				
No	WO 97 04657 A	2/13/97	Micro Therapeutics Inc.			·	
<b>1</b> €	WO 95 27437 A	10/19/95	Mallinckrodt Medical Inc.				
The	EP 0 361 960 A	4/4/90	Ranney David F.	-			

Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

2	Flandroy P. et al., "In vivo behaviour of poly(dl-lactide) microparticles designed for chemoembolization", Journal of Controlled Release, 1997, XP002072471
P	Patent Abstracts of Japan, 013;63 (C-568), 13 February 1989 & JP 63 255231 A, 21 October 1988
B	Patent Abstracts of Japan, 095;002, 31 March 1995 & JP 06 329542 A, 29 November 1994
<b>D</b>	Kunieda K. et al., "Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer", BR. J. CANCER, 1993, USA, XP002072472

Examiner	Hartley	Date Considered 1/4/2000
		, , ,

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.